This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Abbvie Global Enterprises Ltd., Galapagos Nv. Active years: 2022.
Company Filing History:
1 out of 1 
1 out of 116 
Years Active: 2022
Title: Sam Bob Corveleyn: Innovator in Cystic Fibrosis Treatment
Introduction
Sam Bob Corveleyn is a notable inventor based in Mechelen, Belgium. He has made significant contributions to the field of medicine, particularly in the treatment of cystic fibrosis. His innovative work has led to the development of a patent that addresses critical health challenges faced by individuals with this condition.
Latest Patents
Corveleyn holds a patent for "Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use." This invention relates to prodrug compounds and their application in treating cystic fibrosis. It includes methods for producing these compounds, pharmaceutical compositions that incorporate them, and treatment methods for cystic fibrosis through the administration of these innovative compounds.
Career Highlights
Throughout his career, Corveleyn has worked with prominent companies in the pharmaceutical industry. He has been associated with AbbVie Global Enterprises Ltd. and Galapagos NV, where he has contributed to research and development efforts aimed at improving patient outcomes.
Collaborations
Corveleyn has collaborated with esteemed colleagues in his field, including Didier Philippe Robert Schils and Herman Augustinus De Kock. These partnerships have fostered a collaborative environment that enhances innovation and the development of effective treatments.
Conclusion
Sam Bob Corveleyn's work in developing treatments for cystic fibrosis exemplifies the impact of innovation in healthcare. His contributions through patents and collaborations continue to advance medical science and improve the lives of patients.